Last updated 2026-06-18
- Raised $3M funding round, Jul 2018
- Raised $640k grant, Jun 2016
- Raised $750k funding round, May 2016
Total raised
$4.4M
Last: 2018-07
Stage
Series A
Founded
2016
Headcount
3
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences
About
TPCera develops a new type of immunomodulatory compound that shifts the immune system from an inflammatory state into an anti-inflammatory one. The company is focused on shifting macrophages from M1 to M2, which has the potential to modulate autoimmune diseases. TPCera's lead compound is TPC1022. Its subcutaneous and oral administrations have produced promising results in preclinical studies on three autoimmune mice models: lupus, colitis, and rheumatoid arthritis.
Funding history · 3 rounds · $4.4M total
2018-07
2016-06
Grant
$640K
2016-05
Q&A
- What is TPCera's primary focus?
- TPCera develops immunomodulatory compounds to shift the immune system from an inflammatory to an anti-inflammatory state, specifically focusing on modulating autoimmune diseases by shifting macrophages from M1 to M2.
- What is the status of TPCera?
- TPCera is currently inactive, having ceased operations in October 2022.
- When was TPCera founded?
- TPCera was founded in May 2016.
- What is TPCera's lead compound?
- TPCera's lead compound is TPC1022, which has shown promising preclinical results in autoimmune mice models for lupus, colitis, and rheumatoid arthritis.
- What was TPCera's total funding raised?
- TPCera raised a total of $4,390,000 USD.
- Which investors participated in TPCera's July 2018 funding round?
- In July 2018, TPCera received funding from VLX Ventures and Maruho Israel Innovation Fund.
- Which investors participated in TPCera's May 2016 funding round?
- In May 2016, TPCera received funding from VLX Ventures and Docor International Management.
- Did TPCera receive any grants?
- Yes, in June 2016, TPCera received a grant of $640,000 USD from the Israel Innovation Authority.
Team · 3
Founder · Co-founder
Founder · Co-founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesBiotechnologyPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
pharmaceuticalsimmunologycrohn-s-diseasebiopharmaceuticalpharma-companiesdrug-discoveryautoimmune-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2016-5 |
|---|---|
| Employees (exact) | 3 |
| Status reason | Non Active, Oct 2022 ceased to operate |